Cogent Biosciences

COGT

Market cap $6.17B

Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.

WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:30 a.m. GMT (6:30 a.m. ET).

WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 9,677,420 shares of its common stock at a public offering price of $31.00 per share (such offering, the “Equity Offering”) and its underwritten public offering of $200.0 million aggregate principal amount of its 1.625% convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”). The Equity Offering was upsized from the previously announced offering size of $200.0 million of shares of common stock.

Cogent Biosciences, Inc. soared 120% after positive Phase 3 PEAK study results for bezuclastinib in imatinib-resistant GIST patients. COGT's bezuclastinib showed a 50% reduction in disease progression risk and superior objective response rates versus standard of care. Strong PEAK data de-risks upcoming readouts and supports blockbuster revenue projections, with analysts targeting $1.5bn peak sales and a $3-4bn valuation.

WALTHAM, Mass. and BOULDER, Colo.

Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib in 2nd-line GIST. Company's combination therapy showed a significant mPFS improvement (16.5 vs. 9.2 months) and higher ORR (46% vs. 26%) over Sunitinib monotherapy in 2nd-line GIST patients. Upcoming catalysts include NDA filings for GIST in 1H 2026 and NonAdvSM by end of 2025, plus phase 2 APEX results for AdvSM in December 2025.

Cogent Biosciences, Inc. ( COGT ) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 10, 2025 8:00 AM EST Company Participants Christi Waarich - Senior Director of Investor Relations Andrew Robbins - President, CEO & Director Conference Call Participants Neeta Somaiah Anupam Rama - JPMorgan Chase & Co, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Amanda Acosta-Ruiz - Leerink Partners LLC, Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Yuxi Dong - Jefferies LLC, Research Division Presentation Operator Good morning, and welcome to Cogent Biosciences' webcast. I will now turn the call over to Christi Waarich, Senior Director of Investor Relations.

Shares of Cogent Biosciences rocketed to a seven-year high Monday on enthusiasm for the company's experimental stomach cancer treatment.

Cogent Biosciences, Inc. (NASDAQ:COGT) stock is trading higher on Monday, with a session volume of 10.95 million compared to the average volume of 1.97 million as per data from Benzinga Pro.

16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; p